Cargando…

CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance

Metastasis is the primary cause of cancer patient morbidity and mortality, but due to persisting gaps in our knowledge, it remains untreatable. Metastases often occur as patient tumors progress or recur after initial therapy. Tumor recurrence at the primary site may be driven by a cancer stem-like c...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, Brittni M., Zaidi, Danish, Young, Tyler R., Mobley, Mary E., Kerr, Bethany A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874688/
https://www.ncbi.nlm.nih.gov/pubmed/29518044
http://dx.doi.org/10.3390/biomedicines6010031
_version_ 1783310210441412608
author Foster, Brittni M.
Zaidi, Danish
Young, Tyler R.
Mobley, Mary E.
Kerr, Bethany A.
author_facet Foster, Brittni M.
Zaidi, Danish
Young, Tyler R.
Mobley, Mary E.
Kerr, Bethany A.
author_sort Foster, Brittni M.
collection PubMed
description Metastasis is the primary cause of cancer patient morbidity and mortality, but due to persisting gaps in our knowledge, it remains untreatable. Metastases often occur as patient tumors progress or recur after initial therapy. Tumor recurrence at the primary site may be driven by a cancer stem-like cell or tumor progenitor cell, while recurrence at a secondary site is driven by metastatic cancer stem cells or metastasis-initiating cells. Ongoing efforts are aimed at identifying and characterizing these stem-like cells driving recurrence and metastasis. One potential marker for the cancer stem-like cell subpopulation is CD117/c-kit, a tyrosine kinase receptor associated with cancer progression and normal stem cell maintenance. Further, activation of CD117 by its ligand stem cell factor (SCF; kit ligand) in the progenitor cell niche stimulates several signaling pathways driving proliferation, survival, and migration. This review examines evidence that the SCF/CD117 signaling axis may contribute to the control of cancer progression through the regulation of stemness and resistance to tyrosine kinase inhibitors.
format Online
Article
Text
id pubmed-5874688
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58746882018-03-29 CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance Foster, Brittni M. Zaidi, Danish Young, Tyler R. Mobley, Mary E. Kerr, Bethany A. Biomedicines Review Metastasis is the primary cause of cancer patient morbidity and mortality, but due to persisting gaps in our knowledge, it remains untreatable. Metastases often occur as patient tumors progress or recur after initial therapy. Tumor recurrence at the primary site may be driven by a cancer stem-like cell or tumor progenitor cell, while recurrence at a secondary site is driven by metastatic cancer stem cells or metastasis-initiating cells. Ongoing efforts are aimed at identifying and characterizing these stem-like cells driving recurrence and metastasis. One potential marker for the cancer stem-like cell subpopulation is CD117/c-kit, a tyrosine kinase receptor associated with cancer progression and normal stem cell maintenance. Further, activation of CD117 by its ligand stem cell factor (SCF; kit ligand) in the progenitor cell niche stimulates several signaling pathways driving proliferation, survival, and migration. This review examines evidence that the SCF/CD117 signaling axis may contribute to the control of cancer progression through the regulation of stemness and resistance to tyrosine kinase inhibitors. MDPI 2018-03-08 /pmc/articles/PMC5874688/ /pubmed/29518044 http://dx.doi.org/10.3390/biomedicines6010031 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Foster, Brittni M.
Zaidi, Danish
Young, Tyler R.
Mobley, Mary E.
Kerr, Bethany A.
CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
title CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
title_full CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
title_fullStr CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
title_full_unstemmed CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
title_short CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
title_sort cd117/c-kit in cancer stem cell-mediated progression and therapeutic resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874688/
https://www.ncbi.nlm.nih.gov/pubmed/29518044
http://dx.doi.org/10.3390/biomedicines6010031
work_keys_str_mv AT fosterbrittnim cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance
AT zaididanish cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance
AT youngtylerr cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance
AT mobleymarye cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance
AT kerrbethanya cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance